| Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer J Hamanishi, M Mandai, M Iwasaki, T Okazaki, Y Tanaka, K Yamaguchi, ... Proceedings of the National Academy of Sciences 104 (9), 3360-3365, 2007 | 1847 | 2007 |
| Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer J Hamanishi, M Mandai, T Ikeda, M Minami, A Kawaguchi, T Murayama, ... Journal of Clinical Oncology 33 (34), 4015-4022, 2015 | 1113 | 2015 |
| IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer K Abiko, N Matsumura, J Hamanishi, N Horikawa, R Murakami, ... British journal of cancer 112 (9), 1501-1509, 2015 | 730 | 2015 |
| Cancer immunotherapies targeting the PD-1 signaling pathway Y Iwai, J Hamanishi, K Chamoto, T Honjo Journal of biomedical science 24, 1-11, 2017 | 666 | 2017 |
| Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression H Lin, S Wei, EM Hurt, MD Green, L Zhao, L Vatan, W Szeliga, R Herbst, ... The Journal of clinical investigation 128 (2), 805-815, 2018 | 561 | 2018 |
| Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer J Peng, J Hamanishi, N Matsumura, K Abiko, K Murat, T Baba, ... Cancer research 75 (23), 5034-5045, 2015 | 522 | 2015 |
| Dual faces of IFNγ in cancer progression: a role of PD-L1 induction in the determination of pro-and antitumor immunity M Mandai, J Hamanishi, K Abiko, N Matsumura, T Baba, I Konishi Clinical cancer research 22 (10), 2329-2334, 2016 | 395 | 2016 |
| PD-1/PD-L1 blockade in cancer treatment: perspectives and issues J Hamanishi, M Mandai, N Matsumura, K Abiko, T Baba, I Konishi International journal of clinical oncology 21, 462-473, 2016 | 380 | 2016 |
| Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent … K Yamaguchi, M Mandai, S Toyokuni, J Hamanishi, T Higuchi, K Takakura, ... Clinical Cancer Research 14 (1), 32-40, 2008 | 365 | 2008 |
| PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction K Abiko, M Mandai, J Hamanishi, Y Yoshioka, N Matsumura, T Baba, ... Clinical cancer research 19 (6), 1363-1374, 2013 | 251 | 2013 |
| Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells N Horikawa, K Abiko, N Matsumura, J Hamanishi, T Baba, K Yamaguchi, ... Clinical Cancer Research 23 (2), 587-599, 2017 | 250 | 2017 |
| Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation M Taki, K Abiko, T Baba, J Hamanishi, K Yamaguchi, R Murakami, ... Nature communications 9 (1), 1685, 2018 | 246 | 2018 |
| Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes K Yamaguchi, M Mandai, T Oura, N Matsumura, J Hamanishi, T Baba, ... Oncogene 29 (12), 1741-1752, 2010 | 205 | 2010 |
| Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis K Li, M Mandai, J Hamanishi, N Matsumura, A Suzuki, H Yagi, ... Cancer immunology, immunotherapy 58 (5), 641-652, 2009 | 191 | 2009 |
| Immune checkpoint inhibition in ovarian cancer J Hamanishi, M Mandai, I Konishi International immunology 28 (7), 339-348, 2016 | 176 | 2016 |
| Tumor immune microenvironment during epithelial–mesenchymal transition M Taki, K Abiko, M Ukita, R Murakami, K Yamanoi, K Yamaguchi, ... Clinical Cancer Research 27 (17), 4669-4679, 2021 | 164 | 2021 |
| VISTA expressed in tumour cells regulates T cell function K Mulati, J Hamanishi, N Matsumura, K Chamoto, N Mise, K Abiko, ... British journal of cancer 120 (1), 115-127, 2019 | 162 | 2019 |
| Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management K Oda, J Hamanishi, K Matsuo, K Hasegawa Gynecologic oncology 151 (2), 381-389, 2018 | 121 | 2018 |
| Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation gene networks R Murakami, N Matsumura, JB Brown, K Higasa, T Tsutsumi, M Kamada, ... The American journal of pathology 187 (10), 2246-2258, 2017 | 109 | 2017 |
| Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA) J Hamanishi, N Takeshima, N Katsumata, K Ushijima, T Kimura, ... Journal of Clinical Oncology 39 (33), 3671, 2021 | 91 | 2021 |
